Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Current Liabilities
All obligations due within one year.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 105.8% from a year ago
Total current liabilities stood at $39.34M at the end of Q1 FY2026, up 105.8% from a year earlier and up 35.9% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.
Context
- Total current liabilities amounted to 7.1% of total assets at the end of Q1 FY2026, up 3.1 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +105.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 28.95M USD
- Year-over-year change
- +60.9%
- 3-year CAGR
- +6.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.95M | +60.9% |
| FY2024 | 2024-12-31 | 17.99M | +19.3% |
| FY2023 | 2023-12-31 | 15.09M | -36.9% |
| FY2022 | 2022-12-31 | 23.9M | — |
Total Current Liabilities vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total current liabilities of $39.34M is the 2nd highest of the 6 companies compared; the peer median is $14.19M.
- Its year-over-year change of +105.8% is the 3rd highest of 6, against a peer median of +73.0%.
- Total current liabilities amounts to 7.1% of total assets for BCAX, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $95.94M | +73.0% | -3.9% | 44.0% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $39.34M | +105.8% | +6.6% | 7.1% |
| Mar 2026 | $35.15M | +28.5% | +18.8% | 8.7% | |
| Mar 2026 | $14.19M | +442.4% | +59.6% | 7.1% | |
| Mar 2026 | $10.28M | -31.0% | -4.8% | 5.0% | |
| Mar 2026 | $6.53M | +243.9% | +35.7% | 11.1% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $14.19M | +73.0% | +18.8% | 8.7% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.